George Poste is taking on the role of non-executive vice chairman and chief scientific advisor of CDX Holdings, the parent company of Caris Diagnostics and Caris Molecular Diagnostics. Poste also has been named non-executive chairman of Caris Molecular Diagnostics. He has been a director of Caris Diagnostics since November 2006.
Poste is chief scientist of the Complex Adaptive Systems Initiative and director of The Biodesign Institute at Arizona State University. He also is CEO of Health Technology Networks. Between 1992 and 1999, Poste was chief science and technology officer and president of R&D at SmithKline Beecham, prior to its merger with Glaxo Wellcome.
The DNA Repair Company has appointed Brian Ward to be executive VP and it has named Stella Quan to be senior director of product development. Ward formerly was senior VP for Genomic Health. He also has served as president of medical genetic services and senior vice president of operations at Myriad Genetic Laboratories, and he has worked at Genzyme Genetics and at the University of Colorado.
Quan was director of immunoassay development for BioMérieux, was senior director of operations at Tripath Oncology, and she was involved in research and development at Chiron.